Core Viewpoint - Pediatrix Medical Group, Inc. (NYSE:MD) is identified as a promising small-cap stock, with a price target increase from $17 to $24 by Truist Financial, maintaining a Buy rating [1]. Financial Performance - The company experienced a 33.59% increase in share price following the release of its fiscal Q3 2025 results, which showed quarterly revenue of $492.88 million, a decrease of 3.58% year-over-year, but exceeding analysts' estimates by $16.43 million [2]. - Earnings per share (EPS) for the quarter was $0.67, surpassing consensus estimates by $0.20 [2]. Revenue Analysis - The revenue decline was attributed to a portfolio restructuring activity costing approximately $54 million. However, this was mitigated by an 8% growth in same-unit performance, a 7.5% increase in same-unit pricing, and a 40 basis points rise in patient service volumes [3]. EBITDA and Guidance - Adjusted EBITDA for the quarter reached $87 million, exceeding management's expectations, driven by positive pricing outcomes, collections, and expense controls [4]. - The company raised its full-year adjusted EBITDA guidance to a range of $270 million to $290 million, up from the previous range of $245 million to $255 million [4]. Company Overview - Pediatrix Medical Group, Inc. is a leading provider of specialized physician services for women, babies, and children, focusing on newborn, maternal-fetal, and pediatric subspecialty care [5].